Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir

Raltegravir pharmacokinetics was studied in 20 patients included in the ANRS HC30 QUADRIH Study before and after addition of anti-hepatitis C virus (anti-HCV) quadritherapy, including pegylated-interferon–ribavirin and asunaprevir plus daclatasvir. Raltegravir pharmacokinetic parameters remained unc...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Antimicrob Agents Chemother
Autores principales: Barrail-Tran, Aurélie, Vincent, Corine, Furlan, Valérie, Rosa, Isabelle, Rosenthal, Eric, Cheret, Antoine, Molina, Jean-Michel, Taburet, Anne-Marie, Piroth, Lionel
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology 2015
Materias:
Pharmacology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4649172/
https://ncbi.nlm.nih.gov/pubmed/26438504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01603-15
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares